Gilead Announces Phase 2 Data For Investigational All-Oral Regimen Of Sofosbuvir Plus GS-5816 For The Treatment Of Chronic Hepatitis C
November 11, 2014 at 08:03 AM EST
Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from three Phase 2 open-label studies evaluating the safety and efficacy of an ...